Neuroprotection for the new millennium: Matchmaking pharmacology and technology

Annals of the New York Academy of Sciences

Volumn 939, Issue , 2001, Pages 114-125

  Andrews, Russell J ^a,b,c  

^a NASA AMES RESEARCH CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Brain stimulation; Excitotoxic injury; Minimally invasive surgery; Movement disorders; Neuroprotection; Parkinson's disease; Subthalamic nucleus

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BETHANECHOL; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA; CHLORPROMAZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FLUNARIZINE; LEVODOPA; METHYLDOPA; RESERPINE; VALPROIC ACID;

BRAIN DEPTH STIMULATION; CONFERENCE PAPER; DRUG INDUCED DISEASE; HUMAN; MINIMALLY INVASIVE SURGERY; MOTOR DYSFUNCTION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NON INVASIVE MEASUREMENT; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS;

EID: 0034932627     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03618.x     Document Type: Conference Paper

References (23)

1. Neuroprotection in surgery: Development of a pharmacologic cocktail for intraoperative use
2. Stroke therapy: It may be time for an integrative approach
3. Acute stroke treatment trials in the United States
4. Neuroprotective "agents" in surgery: Secret "agent" man, or common "agent" machine?
5. Restoration of neural output from a paralyzed patient by a direct brain connection
6. The molecular pathogenesis of endotoxic shock and organ failure
7. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): Are we winning the battle?
8. Editorial: Prostate cancer diagnostics - obstacles and opportunities
9. Prevention of multiple organ failure
10. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
11. Parkinson's disease
12. Parkinson's disease
13. Drug-induced movement disorders
14. Whatever happened to stereotactic surgery?
15. Combined (thalamotomy and stimulation) stereotactic surgery of the Vim thalamic nucleus for bilateral Parkinson's disease
16. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
17. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
18. A selective toxicity toward cultured mesencephalic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation
19. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
20. Axons, but not cell bodies, are activated by electrical stimulation in cortical gray matter. II. Evidence for selective inactivation of cell bodies and axon initial segments
21. Advances in neurostimulation for movement disorders
22. Mechanisms of deep brain stimulation and future developments
23. Future prospects of brain stimulation